ADA and severe combined immunodeficiency: A pivotal moment came in 2016 with the approval of the first gene therapy drug, Strimvelis (Orchard Therapeutics), by European Medicines Agency (EMA) for the treatment of adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID), a life-threatening monogenic disorder affecting infants.